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The fi rst use in humans of 24 Na-sodium chloride by Hamilton and Stone in 1936 [ 1 ] began a story in which 131 I-iodide became established for treating thyroid disease and radionuclide imaging became routine in hospitals. As important as the fi rst commercial gamma camera (1968) [ 2 ] was the 99m Tc generator, an elegantly simple device that solved the problem of world-wide distribution of a short half-life radionuclide, fi rst used for medical purposes in 1961 [ 2 ] . A range of 99m Tc-radiotracers quickly became available, including complexes of DTPA (renal function, lung ventilation), meso -DMSA (renal perfusion), bisphosphonates (bone), HIDA (liver) and various colloids (predating "nanotechnology" by decades) and macroaggregated albumin. They were easily synthesised in hospitals using simple kit vials, fi rmly establishing 99m Tc as the staple medical radionuclide. They were largely serendipitous, arising from biological experiments using "off the shelf" chelating ligands selected without detailed knowledge of basic technetium chemistry [ 3 ] , which was almost unstudied at that time. The simple preparation disguised extremely complex coordination chemistry. In most cases their structures remain unknown even now, and their approval in today's regulatory climate would have been most unlikely. Nevertheless they were extremely successful.
In the 1980s and 1990s, pioneered by leaders such as Davison and Deutsch, understanding of technetium chemistry grew [ 4 ] producing a new generation of tracers with a greater element of chemical design and with well-defi ned structures, but still with simple, kit-based labelling. The concept of technetium "cores" emerged -well-defi ned, stable complexes adapted to the coordination preferences of technetium, that could be functionalised for different purposes. Examples include the TcO 3+ core (the basis of tracers such as MAG3 complex for renal function imaging, "pentavalent" DMSA complex for medullary thyroid carcinoma and bone disease, HMPAO complex for cerebral perfusion imaging and cell labelling), Tc(isonitrile) 6 + (sestamibi for myocardial perfusion imaging), TcO 2 + (with tetraamine or diphosphine chelating ligands such as tetrofosmin), Tc(CO) 3 + and TcN(dithiocarbamate) 2 .
This set the stage for radiotracer design to shift towards targeting specifi c receptors and transporters, by incorporating 99m Tc into peptides and proteins [ 3 ] , and the term "molecular imaging" became both fashionable and relevant. It remained an important aspiration to synthesise 99m Tc-radiopharmaceuticals via simple processes that are quick and use mild, aqueous conditions, avoiding the need for purifi cation which adds undesirable complexity. However, Tc chemistry is complex, entailing both exchange of ligands and reduction of Tc(VII), and success has been limited. Radiolabelling procedures for biomolecules still involve multiple manipulations and poor specifi c activity. Hydrazinonicotinamide (hynic) and tricarbonyl (Tc(CO) 3 + ) complexes come closest to achieving this, but both fall short and neither has led to commercial products. Due to a shift in commercial interests towards PET, very little effort has been devoted to this problem in the last decade and it remains a challenge to achieve "one-step" 99m Tc biomolecule labelling. Although emergence of positron emission tomography (PET) was roughly contemporaneous with that of the gamma camera, PET only became a routine clinical diagnostic tool in the 1990s, primarily driven by clinical use of the glucose analogue 18 F-fl uorodeoxyglucose. The clinical adoption of PET demanded signifi cant investment in infrastructure, requiring cyclotron installation within 2-4 h travelling distance of PET scanners. Availability of this costly new infrastructure spawned development of a much wider variety of PET tracers to enhance its versatility. Its better resolution and quantifi cation made it increasingly attractive even for applications that do not require organic small molecules, creating roles for metallic positron-emitting radionuclides - 68 Ga (half-life 68 min) is rapidly emerging as "the new technetium" -a short half-life, generator-produced radiometal that is easily introduced into biomolecules. It produces a high positron yield and is readily chelated [ 5 ] with good kinetic stability. Despite growing clinical use, especially in Europe, the fi rst commercial generator received marketing authorisation as recently as 2014. Although gallium chemistry is simpler than that of technetium (with only one relevant oxidation state (III)), the established chelating agents used to couple it to biomolecules require heating, low pH and purifi cation steps, and have not been conducive to use in hospitals with limited radiochemistry facilities. A single-step, kit-based labelling procedure that works at room temperature, moderate pH and very low concentration would greatly increase its utility. Fortunately, considerable efforts have focused recently on developing new chelators to overcome these problems [ 5 ] and we will see their impact soon (Fig. 19.1 ).
Large biomolecules (e.g., monoclonal antibodies) with slow localisation and clearance require longer half-life tracers. The staple long half-life gamma-emitter has been 111 In, which can be attached to proteins using bifunctional chelators, usually DTPA and DOTA. A longer half-life "PET analogue" has inevitably emerged: zirconium-89, and with desferrioxamine B as an effective bifunctional chelator for zirconium, 89 Zr PET has now been used to image the biodistribution and targeting of many antibodies ("immunoPET") in animal models and humans [ 6 ] . Longer-lived radionuclides can also usefully be incorporated into living cells to image their migration in vivo . Tracking leukocytes in this way using 111 In or 99m Tc has been routine since the 1980s. A PET analogue would offer improvements in sensitivity, quantification and resolution suitable for new challenges in cell tracking emerging from the development of cell-based therapies and discoveries in cellular immunology. Indeed, the fi rst 89 Zr cell labelling radiopharmaceuticals have been reported recently [ 7 ] (Fig. 19.2 ) . Refi nement in their chemistry, widespread preclinical and clinical application, and commercial availability may be anticipated in the coming years.
While 64 Cu has been widely studied in the last 20 years as a medium half-life positron emitter for biomolecule labeling, cell tracking and hypoxia imaging, it has begun to give way to alternatives. However its potential to study pathophysiological changes in copper traffi cking (Fig. 19.3 ) in, for example, Wilson's disease, Menkes' disease, dementias (notably Alzheimer's), cancers and nutritional abnormalities [ 8 ] is now emerging. Similar possibilities are emerging to study other essential trace metals such as zinc (using 63 Zn) and manganese (using 52 Mn). This is a new fi eld in which molecular imaging with radionuclides can make a major impact.
The combination of different imaging modalities that complement each other to overcome their individual limitations is a current trend. For example, while PET and SPECT have exquisite sensitivity (sub-picomolar concentrations in vivo) and provide truly "molecular" imaging, their resolution is poor. Magnetic resonance imaging (MRI), on the other hand, offers better anatomical resolution but large amounts of contrast agent are required, while optical imaging can be used at cell level [ 9 ] (unlike radionuclides and MRI) but is restricted in clinical use by poor tissue penetration. A new generation of scanners combining PET and MRI is now entering clinical use, driving new chemistry to produce combined modality contrast agents. For example, incorporating radionuclides into superparamagnetic iron oxide nanoparticles (SPION) allows combination of PET or SPECT with MRI. While particulate radiopharmaceuticals have been clinically used since the earliest days of nuclear medicine, the recent accumulation of capability in design, synthesis and characterisation of nanoparticles greatly enhances potential for multimodality imaging, albeit in specifi c niche areas such as imaging sentinel lymph nodes [ 10 ] (Fig. 19.4 ) , reticuloendothelial system (liver, spleen, bone marrow), tumours (exploiting the enhanced permeability and retention effect), cell labelling and liposome-mediated drug and gene delivery.
In summary, the close cooperation of clinicians, physicists, engineers, biologists and chemists identifi es capabilities, conceives challenges, discovers solutions and applies them in the clinic. Each discipline produces innovations that in turn drive innovations in the others. This is illustrated by the shift in the last decades from single photon radionuclide imaging towards PET, and in turn the emerging shift from PET/CT towards PET/MRI and combination of these with optical imaging [ 9 ] , which has led to new PET and combined modality radiopharmaceuticals. The next decade may see this recapitulated: the development of a new generation of gamma/SPECT scanners with resolution rivalling or exceeding that of PET will encourage renewed use and development of 99m Tc tracers. The recently highlighted global fragility of 99m Tc supply, far from foreshadowing the demise of 99m Tc and SPECT, has stimulated renewed international effort to plan new reactors and cyclotron-based production, and develop new generator designs to cope with lower specifi c activity 99 Mo. This may soon stimulate a reversal in the recent decline of 99m Tc chemistry research, producing innovations appropriate to the age of molecular imaging. New initiatives to develop a whole body PET scanner will stimulate increased use of short half-life radionuclides in combination (e.g., 82 Rb, 62 Cu, 13 N, 18 O) in a research setting, for metabolic characterisation of tissues in unprecedented detail by imaging multiple molecular targets in a single subject, again potentially in combination with MRI and MR spectroscopy. The arrival of cell-based therapies will bring improvements in use of radiopharmaceuticals for cell tracking, again using a multimodality approach. Conversely, the arrival of new, simple chemistry for 68 Ga may drive the installation of more PET scanners.
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